Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

AltaRex in-licenses antibody from NIH for AIT platform

Jan. 14, 2000

Ligand sells Marathon assets to CoPharma

Jan. 14, 2000

Japanese marketing approval no longer sought for Mochida's TNF

Jan. 12, 2000

FDA grants priority review status to Wyeth-Ayerst's therapy for relapsed adult AML

Jan. 11, 2000

New developments announced for AltaRex's ovarian cancer therapy

Jan. 6, 2000

Maxamine granted orphan drug status for AML

Jan. 5, 2000

Cell Genesys receives payment from Japan Tobacco

Jan. 3, 2000

Cel-Sci completes another study in head and neck cancer

Dec. 29, 1999

Impressive early phase II clinical data reported for OvaRex in relapsed ovarian cancer

Dec. 29, 1999

Biomira's BLP25 liposome technology offers promise as cancer therapy

Dec. 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...